Abstract
Brain injury constitutes a disabling health condition of several etiologies. One of the major causes of brain injury is hypoxia-ischemia. Until recently, pharmacological treatments were solely focused on neurons. In the last decades, glial cells started to be considered as alternative targets for neuroprotection. Novel treatments for hypoxia-ischemia intend to modulate reactive forms of glial cells, and/or potentiate their recovery response. In this review, we summarize these neuroprotective strategies in hypoxia-ischemia and discuss their mechanisms of action.
Keywords: brain injury, hypoxia-ischemia, pharmacological treatments, glial cells, neuroprotection
Current Pharmaceutical Design
Title:Neuroprotection in Hypoxic-Ischemic Brain Injury Targeting Glial Cells
Volume: 23 Issue: 26
Author(s): Maria Ines Herrera*, Sofia Mucci*, George E. Barreto, Rodolfo Kolliker-Frers and Francisco Capani*
Affiliation:
- Laboratorio de Citoarquitectura y Plasticidad Neuronal, Facultad de Medicina, Instituto de Investigaciones Cardiologicas Prof. Dr. Alberto C. Taquini (ININCA), UBA-CONICET, CABA, Buenos Aires,Argentina
- Laboratorio de Citoarquitectura y Plasticidad Neuronal, Facultad de Medicina, Instituto de Investigaciones Cardiologicas Prof. Dr. Alberto C. Taquini (ININCA), UBA-CONICET, CABA, Buenos Aires,Argentina
- Laboratorio de Citoarquitectura y Plasticidad Neuronal, Facultad de Medicina, Instituto de Investigaciones Cardiologicas Prof. Dr. Alberto C. Taquini (ININCA), UBA-CONICET, CABA, Buenos Aires,Argentina
Keywords: brain injury, hypoxia-ischemia, pharmacological treatments, glial cells, neuroprotection
Abstract: Brain injury constitutes a disabling health condition of several etiologies. One of the major causes of brain injury is hypoxia-ischemia. Until recently, pharmacological treatments were solely focused on neurons. In the last decades, glial cells started to be considered as alternative targets for neuroprotection. Novel treatments for hypoxia-ischemia intend to modulate reactive forms of glial cells, and/or potentiate their recovery response. In this review, we summarize these neuroprotective strategies in hypoxia-ischemia and discuss their mechanisms of action.
Export Options
About this article
Cite this article as:
Herrera Ines Maria *, Mucci Sofia*, Barreto E. George, Kolliker-Frers Rodolfo and Capani Francisco *, Neuroprotection in Hypoxic-Ischemic Brain Injury Targeting Glial Cells, Current Pharmaceutical Design 2017; 23 (26) . https://dx.doi.org/10.2174/1381612823666170727145422
DOI https://dx.doi.org/10.2174/1381612823666170727145422 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NAD<sup>+</sup>/NADH Metabolism and NAD<sup>+</sup>-Dependent Enzymes in Cell Death and Ischemic Brain Injury: Current Advances and Therapeutic Implications
Current Medicinal Chemistry Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Clinical Significance of the Blood Pressure Changes from Day to Night
Current Hypertension Reviews The Blood-Brain Barrier in Multiple Sclerosis: microRNAs as Key Regulators
CNS & Neurological Disorders - Drug Targets An Implantable Drug-delivery System on a Chip
Current Topics in Medicinal Chemistry Involvement of the Blood-Brain Barrier in Metabolic Regulation
CNS & Neurological Disorders - Drug Targets Anti-Inflammatory Activity of Tetracyclines: Applications to Human Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Current and Experimental Pharmacological Approaches in Neonatal Hypoxic- Ischemic Encephalopathy
Current Pharmaceutical Design Roles of Glutamate and Glutamine Transport in Ammonia Neurotoxicity: State of the Art and Question Marks
Endocrine, Metabolic & Immune Disorders - Drug Targets Metal Nanoparticles for the Treatment and Diagnosis of Neurodegenerative Brain Diseases
Current Pharmaceutical Design Local Treatment for Lymphoid Malignancies of the Eye
Anti-Cancer Agents in Medicinal Chemistry Recent Advances of 1,2,4-triazolo[3,4-α]pyridines: Synthesis and Bioactivities
Current Organic Chemistry Biological Relevance of Lysophospholipids and Green Solutions for Their Synthesis
Current Organic Chemistry Neuroglial Roots of Neurodegenerative Diseases: Therapeutic Potential of Palmitoylethanolamide in Models of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Nutrition, Brain Aging, and Alzheimers Disease
Current Nutrition & Food Science Dynamic Factors Controlling Targeting Nanocarriers to Vascular Endothelium
Current Drug Metabolism Proteomics of Human Pulmonary Surfactant Proteins
Current Proteomics Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma
Mini-Reviews in Medicinal Chemistry Neuronal Generation from Somatic Stem Cells: Current Knowledge and Perspectives on the Treatment of Acquired and Degenerative Central Nervous System Disorders
Current Gene Therapy Molecular Mechanisms, Proteinopathies and Therapeutic Strategies in Neurodegenerative Disorders
Current Genomics